Kissimmee, Florida 34741

  • Ulcerative Colitis

Purpose:

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN (NCT03518086).


Criteria:

Inclusion Criteria: - Have completed Study AMAN (NCT03518086), with at least 1 study drug administration and without early termination of study drug. - Are willing and able to complete the scheduled study assessments, including endoscopy and daily diary entry. - If female, must meet the contraception requirements. Exclusion Criteria: - Participants diagnosed with Crohn's disease or inflammatory bowel disease-unclassified (indeterminate colitis) during the induction study AMAN (NCT03518086). - Participants with a bowel resection or other surgery for the treatment of UC during the previous induction study AMAN (NCT03518086), or are likely to require surgery for the treatment of UC during study AMBG. - Participants with evidence of colonic dysplasia or have been diagnosed with cancer of the gastrointestinal tract during study AMAN (NCT03518086). - Participants diagnosed with clinically important infection including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during the induction study AMAN (NCT03518086). - Participants who initiate a new prohibited medication during the induction study AMAN (NCT03518086). - Participants with certain laboratory abnormalities prior to start of AMBG that would require permanent discontinuation from study drug.


NCT ID:

NCT03524092


Primary Contact:

Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Phone: 1-317-615-4559
Email: ClinicalTrials.gov@lilly.com


Backup Contact:

N/A


Location Contact:

Kissimmee, Florida 34741
United States

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 19, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.